This "promising first step" could help to treat bladder, oral, head and neck tumors more effectively, said biomedical ...

FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive ...

Treatment with Zusduri had a median duration of response of 3.5 years and event-free survival of two years in low-grade ...

A recent study reveals low rates of upper tract urothelial carcinoma in non-muscle-invasive bladder cancer, prompting a ...

The New Brunswick, N.J., pharmaceutical giant on Thursday said the application covers TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle invasive ...

Discover a study that reveals a targetable CA125+ cell state in rare bladder cancer subtypes using single-cell RNA sequencing.

Bladder cancer articles from across Nature Portfolio Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in ...

Johnson & Johnson (NYSE:JNJ) announced on Thursday that the U.S. FDA granted priority review for its new drug application aimed at getting marketing approval for TAR-200, a drug-releasing system for ...